OR WAIT null SECS
June 03, 2022
Astellas and GO Therapeutics will work together to develop novel antibodies for immuno-oncology.
Thermo Fisher Scientific and Qatar Genome Program will use custom genotyping arrays to accelerate genomic research in Qatar.
Cambrex’s acquisition of Q1 Scientific expands the company’s storage services in the European market.
June 01, 2022
GSK’s acquisition of Affinivax will give the company access to their portfolio of next-generation pneumococcal vaccines.
Agenus has entered into three new deals with Targovax, Oxford BioTherapeutics, and Immunogenesis, respectively, doubling its current number of clinical collaborations.
May 26, 2022
Dupixent (dupilumab), developed by Regeneron Pharmaceuticals in partnership with Sanofi, has received FDA approval for a new indication—treating eosinophilic esophagitis, a chronic inflammatory disease.
May 24, 2022
AbbVie and Cugene have reached an exclusive license option agreement for CUG252, Cugene’s lead therapeutic candidate.
AstraZeneca's recombinant COVID-19 vaccine, originally invented by the University of Oxford, has been approved as a third dose booster vaccine in the EU.
EMA has recommended the marketing authorization of Xenpozyme (olipudase alfa) in the European Union.
May 23, 2022
AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.